Progenitor Cell Therapy to Treat Acute Myocardial Infarction: The Promise of High-Dose Autologous CD34+ Bone Marrow Mononuclear Cells
ST elevation myocardial infarction (STEMI) is associated with an increased risk for congestive heart failure and long-term mortality despite the widespread use of thrombolysis and catheter-based revascularization. The need for improved post-STEMI therapies has led to a surge of novel therapeutics, e...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | Stem Cells International |
| Online Access: | http://dx.doi.org/10.1155/2013/658480 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832555074690220032 |
|---|---|
| author | Joseph C. Poole Arshed A. Quyyumi |
| author_facet | Joseph C. Poole Arshed A. Quyyumi |
| author_sort | Joseph C. Poole |
| collection | DOAJ |
| description | ST elevation myocardial infarction (STEMI) is associated with an increased risk for congestive heart failure and long-term mortality despite the widespread use of thrombolysis and catheter-based revascularization. The need for improved post-STEMI therapies has led to a surge of novel therapeutics, especially regenerative approaches using autologous mononuclear cells. Indeed, the past decade has been marked by a number of human trials studying the safety and efficacy of progenitor cell delivery in the post-STEMI setting. While a variety of cell types and delivery techniques have been utilized, directed therapy to the infarct-related artery has been the most widely used approach. From over 1300 subjects randomized in these studies, there is sufficient evidence to conclude that cell therapy after STEMI is uniformly safe, while the efficacy of this intervention for improving outcomes is less clear. Recent meta-analyses have highlighted the importance of both timing of cell delivery, as well as the type, quantity, and mobility of delivered cells as determinants of response. Here, we show the case in which higher doses of CD34+ cells, which are more potent in terms of their migratory capacity, offer the best hope for preserving cardiac function following STEMI. |
| format | Article |
| id | doaj-art-cb72886059a640318deadb7e149f85c0 |
| institution | Kabale University |
| issn | 1687-966X 1687-9678 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Stem Cells International |
| spelling | doaj-art-cb72886059a640318deadb7e149f85c02025-02-03T05:49:44ZengWileyStem Cells International1687-966X1687-96782013-01-01201310.1155/2013/658480658480Progenitor Cell Therapy to Treat Acute Myocardial Infarction: The Promise of High-Dose Autologous CD34+ Bone Marrow Mononuclear CellsJoseph C. Poole0Arshed A. Quyyumi1Emory University School of Medicine, Division of Cardiology, 319 Woodruff Memorial Research Building, 1639 Pierce Drive, Suite 319, Atlanta, GA 30322, USAEmory University School of Medicine, Division of Cardiology, 319 Woodruff Memorial Research Building, 1639 Pierce Drive, Suite 319, Atlanta, GA 30322, USAST elevation myocardial infarction (STEMI) is associated with an increased risk for congestive heart failure and long-term mortality despite the widespread use of thrombolysis and catheter-based revascularization. The need for improved post-STEMI therapies has led to a surge of novel therapeutics, especially regenerative approaches using autologous mononuclear cells. Indeed, the past decade has been marked by a number of human trials studying the safety and efficacy of progenitor cell delivery in the post-STEMI setting. While a variety of cell types and delivery techniques have been utilized, directed therapy to the infarct-related artery has been the most widely used approach. From over 1300 subjects randomized in these studies, there is sufficient evidence to conclude that cell therapy after STEMI is uniformly safe, while the efficacy of this intervention for improving outcomes is less clear. Recent meta-analyses have highlighted the importance of both timing of cell delivery, as well as the type, quantity, and mobility of delivered cells as determinants of response. Here, we show the case in which higher doses of CD34+ cells, which are more potent in terms of their migratory capacity, offer the best hope for preserving cardiac function following STEMI.http://dx.doi.org/10.1155/2013/658480 |
| spellingShingle | Joseph C. Poole Arshed A. Quyyumi Progenitor Cell Therapy to Treat Acute Myocardial Infarction: The Promise of High-Dose Autologous CD34+ Bone Marrow Mononuclear Cells Stem Cells International |
| title | Progenitor Cell Therapy to Treat Acute Myocardial Infarction: The Promise of High-Dose Autologous CD34+ Bone Marrow Mononuclear Cells |
| title_full | Progenitor Cell Therapy to Treat Acute Myocardial Infarction: The Promise of High-Dose Autologous CD34+ Bone Marrow Mononuclear Cells |
| title_fullStr | Progenitor Cell Therapy to Treat Acute Myocardial Infarction: The Promise of High-Dose Autologous CD34+ Bone Marrow Mononuclear Cells |
| title_full_unstemmed | Progenitor Cell Therapy to Treat Acute Myocardial Infarction: The Promise of High-Dose Autologous CD34+ Bone Marrow Mononuclear Cells |
| title_short | Progenitor Cell Therapy to Treat Acute Myocardial Infarction: The Promise of High-Dose Autologous CD34+ Bone Marrow Mononuclear Cells |
| title_sort | progenitor cell therapy to treat acute myocardial infarction the promise of high dose autologous cd34 bone marrow mononuclear cells |
| url | http://dx.doi.org/10.1155/2013/658480 |
| work_keys_str_mv | AT josephcpoole progenitorcelltherapytotreatacutemyocardialinfarctionthepromiseofhighdoseautologouscd34bonemarrowmononuclearcells AT arshedaquyyumi progenitorcelltherapytotreatacutemyocardialinfarctionthepromiseofhighdoseautologouscd34bonemarrowmononuclearcells |